Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 911,692
  • Shares Outstanding, K 19,708
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,090 K
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.89
Trade KRYS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.55
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.64
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -77.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.04 +15.53%
on 11/06/20
48.95 -5.50%
on 10/27/20
-1.89 (-3.93%)
since 10/23/20
3-Month
40.04 +15.53%
on 11/06/20
52.40 -11.71%
on 10/16/20
-1.44 (-3.02%)
since 08/25/20
52-Week
33.08 +39.82%
on 03/18/20
66.85 -30.80%
on 02/13/20
-10.70 (-18.79%)
since 11/25/19

Most Recent Stories

More News
Krystal Biotech to Present at the Evercore ISI HealthCONx Conference

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan, chairman and chief executive officer will be participating...

KRYS : 46.26 (-1.53%)
Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress

--- Initiated the Phase 1 Study of KB301 in Facial Wrinkles and Acne Scars

KRYS : 46.26 (-1.53%)
Krystal Biotech Announces Departure of Chief Commercial Officer

Krystal Biotech, Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal's commercial...

KRYS : 46.26 (-1.53%)
Krystal Biotech to Present Pre-clinical Data Highlighting KB301 for Aesthetic Indications at the ASDS 2020 Virtual Meeting

--- The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne scars and fine wrinkles is currently enrolling

KRYS : 46.26 (-1.53%)
Krystal Biotech to Present at Upcoming Investor Conferences

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that...

KRYS : 46.26 (-1.53%)
Krystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare Conferences

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that...

MS : 63.48 (-0.19%)
KRYS : 46.26 (-1.53%)
Krystal Biotech's KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis

Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that the U.S. Food...

KRYS : 46.26 (-1.53%)
Krystal Biotech to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Krish...

KRYS : 46.26 (-1.53%)
Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock

Krystal Biotech, Inc. (Nasdaq: KRYS) (the "Company"), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced...

KRYS : 46.26 (-1.53%)
Krystal Biotech Announces Proposed Public Offering of Common Stock

Krystal Biotech, Inc. (Nasdaq: KRYS) (the "Company"), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced...

KRYS : 46.26 (-1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

2nd Resistance Point 49.26
1st Resistance Point 47.76
Last Price 46.26
1st Support Level 44.91
2nd Support Level 43.56

See More

52-Week High 66.85
Fibonacci 61.8% 53.95
Fibonacci 50% 49.97
Last Price 46.26
Fibonacci 38.2% 45.98
52-Week Low 33.08

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar